Blood Test Based on DNA Changes to Help Diagnose Pancreatic Cancer
Tests a blood test for pancreatic cancer using DNA changes in adults.
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Glen Burnie, United StatesSee the site
- Trial code
- Registry title
- Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
- Status
- Not yet recruiting
- People taking part
- 450 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- Mar 2033
- Type of study
- Observational, 3 groups
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are patients at UMMS and have had pancreatic cancer or are at high risk for it. They give blood samples and fill out questionnaires.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A history of pancreatic cancer, or high risk for pancreatic cancer. The record lists the condition as advanced or metastatic pancreatic cancer.
Main reasons for not taking part
- Younger than 18 years old
- Not cared for at UMMS
- Unable to consent to the study procedures
- Unable to speak or understand English
- No history of pancreatic cancer and not at high risk for it
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- 18 years old or older
- Patient of UMMS
- Willing and able to consent to study procedures listed in the protocol
- Ability to speak and understand English
- Has a history of pancreatic cancer of is at high risk for pancreatic cancer
Who cannot take part
- Does not have a history of pancreatic cancer or is not at high risk for pancreatic cancer
- Younger than 18 years old
- Patient not cared for at UMMS
- Unable to consent to study procedures listed in the protocol
- Unable to speak or understand English
Where in United States
- University of Maryland Baltimore Washington Medical CenterGlen Burnie, United StatesContact: Peter Olivieri, MDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.
Read full original descriptionShow less
Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
The 3 groups in the trial
- Study Population 1
This study population will consist of individuals who have a diagnosis of pancreatic cancer and have not received chemotherapy treatment for their pancreatic cancer. Individuals who have received surgical resection and/or radiation therapy for their pancreatic cancer will be included.
- Study Population 2
This study population will consist of individuals who have a diagnosis of pancreatic cancer and have received chemotherapy treatment for their pancreatic cancer. All stages of pancreatic cancer will be included including individuals in remission.
- Study Population 3
This study population will consist of individuals who are at high risk of developing pancreatic cancer.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
- Plain-language title
- Blood Test Based on DNA Changes to Help Diagnose Pancreatic CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 6 November 2026